Entity information:

11. Income Taxes

For the years ended December 31, 2017, 2016 and 2015, the Company recorded no income tax benefit for the net operating losses incurred in each year, due to its uncertainty of realizing a benefit from those items.

A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations as of December 31, 2017, 2016 and 2015 are as follows:

 

 

 

 

 

 

 

 

 

    

2017

    

2016

 

2015

 

Income tax computed at federal statutory tax rate

 

34.0

%  

34.0

%

34.0

%

State taxes, net of federal benefit

 

5.1

%  

5.1

%

5.4

%

Permanent differences

 

(0.8)

%  

(1.3)

%

(0.6)

%

Research and development expenditures

 

(2.3)

%  

 —

%  

 —

%  

General business credits

 

8.2

%  

12.9

%

7.3

%

Impact of tax reform

 

(27.3)

%  

 —

%

 —

%

Section 382 adjustment for net operating losses and credits

 

 —

%  

 —

%

(120.1)

%

Other

 

 —

%  

(0.1)

%

(0.2)

%

Change in valuation allowance

 

(16.9)

%  

(50.6)

%

74.2

%

 

 

 —

%  

 —

%

 —

%

 

On December 22, 2017, legislation commonly known as the Tax Cuts and Jobs Act (the Tax Act) was signed into law. The Tax Act, among other changes, reduces the U.S. federal corporate tax rate from 35% to 21%, requires taxpayers to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign sourced earnings. As of December 31, 2017, the Company did not have any foreign subsidiaries and the international aspects of the Tax Act are not applicable.

The Company is still in the process of analyzing the impact to the Company of the Tax Act. On December 22, 2017, the SEC staff issued SAB 118 to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The Company has recognized the provisional tax impacts related to the revaluation of the deferred tax assets and liabilities and included these amounts in its consolidated financial statements for the year ended December 31, 2017. The ultimate impact may differ from these provisional amounts due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Act, which could result in changes to the provisional tax impacts during 2018.

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets as of December 31, 2017 and 2016 are as follows:

 

 

 

 

 

 

 

 

    

2017

    

2016

Deferred tax assets:

 

 

  

 

 

  

Net operating losses

 

$

9,324

 

$

9,263

Tax credit carryforwards

 

 

7,516

 

 

4,055

Deferred revenue

 

 

13,718

 

 

11,061

Licensed technology

 

 

1,266

 

 

856

Depreciation

 

 

268

 

 

286

Accrued expenses

 

 

53

 

 

215

Deferred expenses

 

 

313

 

 

180

Unrealized loss

 

 

41

 

 

 —

Other state credits

 

 

103

 

 

75

Total deferred tax assets

 

 

32,602

 

 

25,991

Valuation allowance

 

 

(32,602)

 

 

(25,991)

Net deferred tax assets

 

$

 —

 

$

 —

 

The Company has incurred net operating losses (“NOL”) since inception. At December 31, 2017, the Company had Federal and State net operating loss carryforwards of approximately $34,200 and $33,900, respectively, which expire at various dates through 2037. At December 31, 2017, the Company had Federal and State research and development tax credit carryforwards of approximately $5,600 and $2,600, respectively, which expire at various dates through 2037.

As required by ASC 740, management of the Company has evaluated the evidence bearing upon the reliability of its deferred tax assets. Based on the weight of available evidence, both positive and negative, management has determined that it is more likely than not that the Company will not realize the benefits of these assets. Accordingly, the Company recorded a valuation allowance of $32,602 and $25,991 at December 31, 2017 and December 31, 2016, respectively. The valuation allowance increased by $6,611 and $6,930 during the years ended December 31, 2017 and 2016, respectively, primarily as a result of net operating losses generated during the periods.

Utilization of the NOLs and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section 382, as well as similar state provisions. These ownership changes may limit the amount of NOLs and research and development tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. If a change in control as defined by Section 382 has occurred at any time since the Company’s formation, utilization of its NOLs or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate, which could then be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOLs or research and development tax carryforwards before their utilization. The Company has determined that ownership changes have occurred through December 31, 2015 and that certain NOLs and research and development tax credit carryforwards will be subject to limitation. The amounts presented do not include NOLs or research and development tax credit carryforwards that will expire unused due to ownership changes.

The Company applies the accounting guidance in ASC 740 related to accounting for uncertainty in income taxes. The Company’s reserves related to taxes are based on a determination of whether, and how much of, a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. As of December 31, 2017 and 2016, the Company had no unrecognized tax benefits.

The Company has not conducted a study of its research and development credit carryforwards. This study may result in an adjustment to research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations if an adjustment were required.

Interest and penalties related to uncertain tax positions would be classified as income tax expense in the accompanying statements of operations. As of December 31, 2017 and 2016, the Company had no accrued interest or penalties related to uncertain tax positions.

The Company files income tax returns in the United States federal tax jurisdiction and one state jurisdiction. The Company did not have any foreign operations during the years ended December 31, 2017, 2016 and 2015. The statute of limitations for assessment by the Internal Revenue Service and state tax authorities is closed for tax years prior to 2014, although carryforward attributes that were generated prior to tax year 2014 may still be adjusted upon examination to the extent utilized in a future period. There are currently no federal or state audits in progress.